{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"30.0"},{"groupId":"OG001","spread":"0","value":"30.0"}]}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.1","value":"797.3"},{"groupId":"OG001","spread":"191.8","value":"1328.5"}]}],"title":"Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.7","value":"912.1"},{"groupId":"OG001","spread":"44.3","value":"989.0"}]}],"title":"Cycle 1 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Data is only available for Part 1, for Part 2 inadequate samples were collected to fully evaluate separate PK parameters after doses 1, 2, and 3.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Tisotumab vedotin 0.9 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).","id":"OG000","title":"Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg"},{"description":"Tisotumab vedotin 1.2 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).","id":"OG001","title":"Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Insufficient samples were taken in Cycle 2 and beyond to calculate PK parameters, therefore only Cycle 1 is reported.","reportingStatus":"POSTED","timeFrame":"Before infusion of Day 1, 8 and 15 of Cycle 1","title":"Part 1: Trough Concentration (Ctrough) Steady State Plasma Pharmacokinetic for Tisotumab Vedotin (HuMax-TF-ADC)","type":"SECONDARY","unitOfMeasure":"ng/mL"}